$HAE
HAEMONETICS CORP

2021 Q4 Form 10-Q Financial Statement

#000031314321000052 Filed on November 09, 2021

View on sec.gov

Income Statement

Concept 2021 Q4 2020 Q3
Revenue $239.9M $209.5M
YoY Change -0.2% -17.06%
Cost Of Revenue $117.4M $103.7M
YoY Change -2.3% -17.38%
Gross Profit $122.5M $105.7M
YoY Change 1.9% -16.74%
Gross Profit Margin 51.08% 50.48%
Selling, General & Admin $75.78M $63.57M
YoY Change 15.44% -18.42%
% of Gross Profit 61.84% 60.12%
Research & Development $10.85M $6.763M
YoY Change 44.69% -8.88%
% of Gross Profit 8.86% 6.4%
Depreciation & Amortization $23.53M $20.90M
YoY Change 13.14% -22.88%
% of Gross Profit 19.21% 19.76%
Operating Expenses $98.03M $46.96M
YoY Change 22.8% -39.22%
Operating Profit $24.51M $58.78M
YoY Change -39.37% 18.18%
Interest Expense -$4.588M -$3.800M
YoY Change 48.0% -19.15%
% of Operating Profit -18.72% -6.46%
Other Income/Expense, Net -$4.588M -$3.826M
YoY Change 50.38% -17.74%
Pretax Income $19.92M $54.96M
YoY Change -46.7% 21.89%
Income Tax $5.100M $6.900M
% Of Pretax Income 25.6% 12.56%
Net Earnings $14.86M $48.10M
YoY Change -53.4% 28.32%
Net Earnings / Revenue 6.19% 22.96%
Basic Earnings Per Share $0.29 $0.95
Diluted Earnings Per Share $0.29 $0.94
COMMON SHARES
Basic Shares Outstanding 51.04M shares 50.70M shares
Diluted Shares Outstanding 51.46M shares 51.09M shares

Balance Sheet

Concept 2021 Q4 2020 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $192.4M $279.2M
YoY Change 1.81% 149.29%
Cash & Equivalents $192.4M $279.2M
Short-Term Investments
Other Short-Term Assets $42.86M $34.40M
YoY Change 31.07% -0.86%
Inventory $322.7M $305.2M
Prepaid Expenses
Receivables $141.3M $141.5M
Other Receivables $0.00 $0.00
Total Short-Term Assets $699.2M $760.3M
YoY Change 4.62% 33.9%
LONG-TERM ASSETS
Property, Plant & Equipment $223.7M $240.4M
YoY Change -6.78% -9.02%
Goodwill $468.6M $214.6M
YoY Change 117.44% 1.68%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $66.60M $71.38M
YoY Change -4.76% 141.11%
Total Long-Term Assets $1.102B $657.9M
YoY Change 69.65% 5.64%
TOTAL ASSETS
Total Short-Term Assets $699.2M $760.3M
Total Long-Term Assets $1.102B $657.9M
Total Assets $1.801B $1.418B
YoY Change 36.68% 19.12%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $44.97M $49.07M
YoY Change 4.63% -14.58%
Accrued Expenses $41.07M $29.20M
YoY Change 17.0% -24.74%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $82.73M $167.0M
YoY Change 385.1% 193.32%
Total Short-Term Liabilities $288.5M $338.6M
YoY Change 48.4% 41.03%
LONG-TERM LIABILITIES
Long-Term Debt $698.0M $297.0M
YoY Change 138.47% -5.4%
Other Long-Term Liabilities $91.86M $104.2M
YoY Change -9.95% 153.81%
Total Long-Term Liabilities $789.9M $401.2M
YoY Change 100.11% 13.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $288.5M $338.6M
Total Long-Term Liabilities $789.9M $401.2M
Total Liabilities $1.078B $739.8M
YoY Change 83.05% 24.31%
SHAREHOLDERS EQUITY
Retained Earnings $169.4M $137.1M
YoY Change 0.23% 60.15%
Common Stock $558.7M $569.3M
YoY Change -3.68% 6.56%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $698.5M $667.9M
YoY Change
Total Liabilities & Shareholders Equity $1.801B $1.418B
YoY Change 36.68% 19.12%

Cashflow Statement

Concept 2021 Q4 2020 Q3
OPERATING ACTIVITIES
Net Income $14.86M $48.10M
YoY Change -53.4% 28.32%
Depreciation, Depletion And Amortization $23.53M $20.90M
YoY Change 13.14% -22.88%
Cash From Operating Activities $43.46M $29.20M
YoY Change -34.45% -2.34%
INVESTING ACTIVITIES
Capital Expenditures -$20.81M -$8.300M
YoY Change 121.4% -12.63%
Acquisitions
YoY Change
Other Investing Activities $292.0K $45.50M
YoY Change -246.0% 195.45%
Cash From Investing Activities -$20.52M $37.10M
YoY Change 116.0% 528.81%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -3.315M -64.40M
YoY Change -97.79% -42.76%
NET CHANGE
Cash From Operating Activities 43.46M 29.20M
Cash From Investing Activities -20.52M 37.10M
Cash From Financing Activities -3.315M -64.40M
Net Change In Cash 19.63M 1.900M
YoY Change -121.08% -102.48%
FREE CASH FLOW
Cash From Operating Activities $43.46M $29.20M
Capital Expenditures -$20.81M -$8.300M
Free Cash Flow $64.27M $37.50M
YoY Change -15.1% -4.82%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0000313143
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--04-02
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
CY2021Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
2701000 USD
CY2021Q2 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
2226000 USD
CY2021Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
348336000 USD
CY2021Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
320640000 USD
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2021Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2021Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
51060192 shares
CY2021Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
50868820 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
51060192 shares
CY2021Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
50868820 shares
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2021-10-02
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-14041
dei Local Phone Number
LocalPhoneNumber
848-7100
dei Entity Registrant Name
EntityRegistrantName
HAEMONETICS CORP
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
MA
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
04-2882273
dei Entity Address Address Line1
EntityAddressAddressLine1
125 Summer Street
dei Entity Address City Or Town
EntityAddressCityOrTown
Boston,
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02110
dei City Area Code
CityAreaCode
781
dei Security12b Title
Security12bTitle
Common stock, $.01 par value per share
dei Trading Symbol
TradingSymbol
HAE
dei Security Exchange Name
SecurityExchangeName
NYSE
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2021Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
51105232 shares
CY2021Q4 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
239897000 USD
CY2020Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
209486000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
468425000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
405063000 USD
CY2021Q4 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
117356000 USD
CY2020Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
103742000 USD
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
237799000 USD
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
209289000 USD
CY2021Q4 us-gaap Gross Profit
GrossProfit
122541000 USD
CY2020Q3 us-gaap Gross Profit
GrossProfit
105744000 USD
us-gaap Gross Profit
GrossProfit
230626000 USD
us-gaap Gross Profit
GrossProfit
195774000 USD
CY2021Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10853000 USD
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6763000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
23554000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
14513000 USD
CY2021Q4 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
75778000 USD
CY2020Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
63570000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
166996000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
125863000 USD
CY2021Q4 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
11400000 USD
CY2020Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
8127000 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
23779000 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
16399000 USD
CY2021Q4 hae Gain Loss On Divestiture And Sale Of Assets
GainLossOnDivestitureAndSaleOfAssets
0 USD
CY2020Q3 hae Gain Loss On Divestiture And Sale Of Assets
GainLossOnDivestitureAndSaleOfAssets
31498000 USD
hae Gain Loss On Divestiture And Sale Of Assets
GainLossOnDivestitureAndSaleOfAssets
9603000 USD
hae Gain Loss On Divestiture And Sale Of Assets
GainLossOnDivestitureAndSaleOfAssets
31498000 USD
CY2021Q4 us-gaap Operating Expenses
OperatingExpenses
98031000 USD
CY2020Q3 us-gaap Operating Expenses
OperatingExpenses
46962000 USD
us-gaap Operating Expenses
OperatingExpenses
204726000 USD
us-gaap Operating Expenses
OperatingExpenses
125277000 USD
CY2021Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
24510000 USD
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
58782000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
25900000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
70497000 USD
CY2021Q4 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-4588000 USD
CY2020Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-3826000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-8986000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-7561000 USD
CY2021Q4 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
19922000 USD
CY2020Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
54956000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
16914000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
62936000 USD
CY2021Q4 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
5066000 USD
CY2020Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
6855000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
6512000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
4308000 USD
CY2021Q4 us-gaap Net Income Loss
NetIncomeLoss
14856000 USD
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
48101000 USD
us-gaap Net Income Loss
NetIncomeLoss
10402000 USD
us-gaap Net Income Loss
NetIncomeLoss
58628000 USD
CY2021Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.29
CY2020Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.95
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.20
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.16
CY2021Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.29
CY2020Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.94
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.20
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.15
CY2021Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
51039000 shares
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
50696000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
50557000 shares
CY2021Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
51458000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
50989000 shares
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
51093000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
51358000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
51170000 shares
CY2021Q4 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
14420000 USD
CY2020Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
53335000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
10413000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
65291000 USD
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
192420000 USD
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
192305000 USD
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
141305000 USD
CY2021Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
127555000 USD
CY2021Q4 us-gaap Inventory Net
InventoryNet
322661000 USD
CY2021Q2 us-gaap Inventory Net
InventoryNet
322614000 USD
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
42860000 USD
CY2021Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
51072000 USD
CY2021Q4 us-gaap Assets Current
AssetsCurrent
699246000 USD
CY2021Q2 us-gaap Assets Current
AssetsCurrent
693546000 USD
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
223747000 USD
CY2021Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
217559000 USD
CY2021Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
337249000 USD
CY2021Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
365483000 USD
CY2021Q4 us-gaap Goodwill
Goodwill
468590000 USD
CY2021Q2 us-gaap Goodwill
Goodwill
466444000 USD
CY2021Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
6064000 USD
CY2021Q2 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
6009000 USD
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
66601000 USD
CY2021Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
70882000 USD
CY2021Q4 us-gaap Assets
Assets
1801497000 USD
CY2021Q2 us-gaap Assets
Assets
1819923000 USD
CY2021Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
82733000 USD
CY2021Q2 us-gaap Long Term Debt Current
LongTermDebtCurrent
17016000 USD
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
44969000 USD
CY2021Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
50293000 USD
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
41067000 USD
CY2021Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
47600000 USD
CY2021Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
119701000 USD
CY2021Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
138586000 USD
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
288470000 USD
CY2021Q2 us-gaap Liabilities Current
LiabilitiesCurrent
253495000 USD
CY2021Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
698043000 USD
CY2021Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
690592000 USD
CY2021Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
24574000 USD
CY2021Q2 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
43825000 USD
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
91861000 USD
CY2021Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
100341000 USD
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
511000 USD
CY2021Q2 us-gaap Common Stock Value
CommonStockValue
509000 USD
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
558156000 USD
CY2021Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
602727000 USD
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
169418000 USD
CY2021Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
157981000 USD
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-29536000 USD
CY2021Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-29547000 USD
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
698549000 USD
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
731670000 USD
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1801497000 USD
CY2021Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1819923000 USD
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
731670000 USD
CY2021Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
2210000 USD
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
500000 USD
CY2021Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0 USD
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6828000 USD
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-4454000 USD
CY2021Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
447000 USD
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
677080000 USD
CY2021Q4 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1070000 USD
CY2021Q4 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5979000 USD
CY2021Q4 us-gaap Net Income Loss
NetIncomeLoss
14856000 USD
CY2021Q4 us-gaap Net Income Loss
NetIncomeLoss
14856000 USD
CY2021Q4 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-436000 USD
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
698549000 USD
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
587109000 USD
CY2020Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
2144000 USD
CY2020Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1193000 USD
CY2020Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0 USD
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6167000 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
10527000 USD
CY2020Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
1429000 USD
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
608569000 USD
CY2020Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
67000 USD
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5952000 USD
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
48101000 USD
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
48101000 USD
CY2020Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
5234000 USD
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
667923000 USD
us-gaap Net Income Loss
NetIncomeLoss
10402000 USD
us-gaap Net Income Loss
NetIncomeLoss
10402000 USD
us-gaap Net Income Loss
NetIncomeLoss
58628000 USD
us-gaap Depreciation And Amortization
DepreciationAndAmortization
48567000 USD
us-gaap Depreciation And Amortization
DepreciationAndAmortization
41603000 USD
hae Amortization Of Fair Value Inventory Step Up
AmortizationOfFairValueInventoryStepUp
5295000 USD
hae Amortization Of Fair Value Inventory Step Up
AmortizationOfFairValueInventoryStepUp
0 USD
us-gaap Asset Impairment Charges
AssetImpairmentCharges
5144000 USD
us-gaap Asset Impairment Charges
AssetImpairmentCharges
1028000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
12807000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
12119000 USD
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
1813000 USD
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
286000 USD
us-gaap Provision For Loan Lease And Other Losses
ProvisionForLoanLeaseAndOtherLosses
114000 USD
us-gaap Provision For Loan Lease And Other Losses
ProvisionForLoanLeaseAndOtherLosses
1057000 USD
hae Gain Loss On Divestiture And Sale Of Assets
GainLossOnDivestitureAndSaleOfAssets
9603000 USD
hae Gain Loss On Divestiture And Sale Of Assets
GainLossOnDivestitureAndSaleOfAssets
31498000 USD
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
898000 USD
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-3031000 USD
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
9345000 USD
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
0 USD
us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
861000 USD
us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
76000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
14574000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-22391000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
5475000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
38189000 USD
us-gaap Increase Decrease In Prepaid Taxes
IncreaseDecreaseInPrepaidTaxes
-2477000 USD
us-gaap Increase Decrease In Prepaid Taxes
IncreaseDecreaseInPrepaidTaxes
635000 USD
us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
842000 USD
us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
-1902000 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-25449000 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-24770000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
41780000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
40967000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
34731000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
16035000 USD
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
2500000 USD
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
16606000 USD
us-gaap Proceeds From Divestiture Of Businesses
ProceedsFromDivestitureOfBusinesses
0 USD
us-gaap Proceeds From Divestiture Of Businesses
ProceedsFromDivestitureOfBusinesses
44978000 USD
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
860000 USD
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
902000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-36371000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
13239000 USD
us-gaap Proceeds From Repayments Of Short Term Debt
ProceedsFromRepaymentsOfShortTermDebt
0 USD
us-gaap Proceeds From Repayments Of Short Term Debt
ProceedsFromRepaymentsOfShortTermDebt
90000000 USD
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
8750000 USD
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
8750000 USD
us-gaap Employee Stock Ownership Plan Esop Cash Contributions To Esop
EmployeeStockOwnershipPlanESOPCashContributionsToESOP
2210000 USD
us-gaap Employee Stock Ownership Plan Esop Cash Contributions To Esop
EmployeeStockOwnershipPlanESOPCashContributionsToESOP
2144000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1569000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1259000 USD
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
22000 USD
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-20000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-4949000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
84633000 USD
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-345000 USD
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3019000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
115000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
141858000 USD
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
192305000 USD
CY2020Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
137311000 USD
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
192420000 USD
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
279169000 USD
hae Transfers From Inventory To Fixed Assets
TransfersFromInventoryToFixedAssets
10139000 USD
hae Transfers From Inventory To Fixed Assets
TransfersFromInventoryToFixedAssets
4203000 USD
CY2021Q2 us-gaap Restructuring Reserve
RestructuringReserve
1012000 USD
us-gaap Restructuring Charges
RestructuringCharges
4115000 USD
us-gaap Payments For Restructuring
PaymentsForRestructuring
1459000 USD
CY2021Q4 us-gaap Restructuring Reserve
RestructuringReserve
3668000 USD
CY2021Q4 us-gaap Restructuring Charges
RestructuringCharges
695000 USD
CY2020Q3 us-gaap Restructuring Charges
RestructuringCharges
-73000 USD
us-gaap Restructuring Charges
RestructuringCharges
4115000 USD
us-gaap Restructuring Charges
RestructuringCharges
992000 USD
CY2021Q4 us-gaap Restructuring Reserve
RestructuringReserve
3700000 USD
CY2021Q4 hae Restructuring Charges Payable In Next Twelve Months
RestructuringChargesPayableInNextTwelveMonths
3200000 USD
CY2021Q4 us-gaap Restructuring Charges
RestructuringCharges
695000 USD
CY2020Q3 us-gaap Restructuring Charges
RestructuringCharges
-73000 USD
us-gaap Restructuring Charges
RestructuringCharges
4115000 USD
us-gaap Restructuring Charges
RestructuringCharges
992000 USD
CY2021Q4 hae Restructuring Related Costs
RestructuringRelatedCosts
3818000 USD
CY2020Q3 hae Restructuring Related Costs
RestructuringRelatedCosts
4513000 USD
hae Restructuring Related Costs
RestructuringRelatedCosts
10453000 USD
hae Restructuring Related Costs
RestructuringRelatedCosts
7448000 USD
CY2021Q4 hae Restructuringand Restructuring Related Costs
RestructuringandRestructuringRelatedCosts
4513000 USD
CY2020Q3 hae Restructuringand Restructuring Related Costs
RestructuringandRestructuringRelatedCosts
4440000 USD
hae Restructuringand Restructuring Related Costs
RestructuringandRestructuringRelatedCosts
14568000 USD
hae Restructuringand Restructuring Related Costs
RestructuringandRestructuringRelatedCosts
8440000 USD
CY2021Q4 us-gaap Business Combination Separately Recognized Transactions Additional Disclosures Acquisition Cost Expensed
BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed
200000 USD
CY2021Q4 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
5100000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
6500000 USD
CY2021Q4 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.254
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.385
CY2021Q4 us-gaap Tax Adjustments Settlements And Unusual Provisions
TaxAdjustmentsSettlementsAndUnusualProvisions
100000 USD
us-gaap Tax Adjustments Settlements And Unusual Provisions
TaxAdjustmentsSettlementsAndUnusualProvisions
900000 USD
CY2020Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
6900000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
4300000 USD
CY2020Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.125
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.068
CY2020Q3 us-gaap Tax Adjustments Settlements And Unusual Provisions
TaxAdjustmentsSettlementsAndUnusualProvisions
-100000 USD
us-gaap Tax Adjustments Settlements And Unusual Provisions
TaxAdjustmentsSettlementsAndUnusualProvisions
-4100000 USD
CY2021Q4 us-gaap Net Income Loss
NetIncomeLoss
14856000 USD
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
48101000 USD
us-gaap Net Income Loss
NetIncomeLoss
10402000 USD
us-gaap Net Income Loss
NetIncomeLoss
10402000 USD
us-gaap Net Income Loss
NetIncomeLoss
58628000 USD
CY2021Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
51039000 shares
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
50696000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
50989000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
50557000 shares
CY2021Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.29
CY2020Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.95
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.20
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.16
CY2021Q4 us-gaap Net Income Loss
NetIncomeLoss
14856000 USD
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
48101000 USD
us-gaap Net Income Loss
NetIncomeLoss
10402000 USD
us-gaap Net Income Loss
NetIncomeLoss
58628000 USD
CY2021Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
51039000 shares
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
50696000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
50989000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
50557000 shares
CY2021Q4 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
419000 shares
CY2020Q3 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
397000 shares
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
369000 shares
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
613000 shares
CY2021Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
51458000 shares
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
51093000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
51358000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
51170000 shares
CY2021Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.29
CY2020Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.94
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.20
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.15
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
900000 shares
CY2020Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
800000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
600000 shares
CY2021Q4 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
21000000 USD
CY2021Q4 us-gaap Revenue Remaining Performance Obligation Percentage
RevenueRemainingPerformanceObligationPercentage
0.68
CY2021Q4 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P12M
CY2021Q4 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
4400000 USD
CY2021Q2 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
4800000 USD
CY2021Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
23900000 USD
CY2021Q2 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
20900000 USD
CY2021Q4 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
4600000 USD
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
13200000 USD
CY2021Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
81950000 USD
CY2021Q2 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
74910000 USD
CY2021Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
22909000 USD
CY2021Q2 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
23111000 USD
CY2021Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
217802000 USD
CY2021Q2 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
224593000 USD
CY2021Q4 us-gaap Inventory Net
InventoryNet
322661000 USD
CY2021Q2 us-gaap Inventory Net
InventoryNet
322614000 USD
CY2021Q3 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
2236000 USD
CY2020Q2 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
3446000 USD
CY2021Q2 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
2226000 USD
CY2020Q1 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
3824000 USD
CY2021Q4 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
-504000 USD
CY2020Q3 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
483000 USD
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
-532000 USD
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
742000 USD
CY2021Q4 us-gaap Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
39000 USD
CY2020Q3 us-gaap Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
264000 USD
us-gaap Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
57000 USD
us-gaap Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
383000 USD
CY2021Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
2701000 USD
CY2020Q3 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
2699000 USD
CY2021Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
2701000 USD
CY2020Q3 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
2699000 USD
CY2021Q4 hae Net Revenues Before Foreign Exchange Impact
NetRevenuesBeforeForeignExchangeImpact
233165000 USD
CY2020Q3 hae Net Revenues Before Foreign Exchange Impact
NetRevenuesBeforeForeignExchangeImpact
204455000 USD
hae Net Revenues Before Foreign Exchange Impact
NetRevenuesBeforeForeignExchangeImpact
454311000 USD
hae Net Revenues Before Foreign Exchange Impact
NetRevenuesBeforeForeignExchangeImpact
398055000 USD
CY2021Q4 hae Effectof Exchange Rateon Revenues
EffectofExchangeRateonRevenues
1781000 USD
CY2020Q3 hae Effectof Exchange Rateon Revenues
EffectofExchangeRateonRevenues
-311000 USD
hae Effectof Exchange Rateon Revenues
EffectofExchangeRateonRevenues
3895000 USD
hae Effectof Exchange Rateon Revenues
EffectofExchangeRateonRevenues
-3416000 USD
CY2021Q4 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
239897000 USD
CY2020Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
209486000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
468425000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
405063000 USD
CY2021Q4 hae Effectof Exchange Rateson Operating Income
EffectofExchangeRatesonOperatingIncome
3934000 USD
CY2020Q3 hae Effectof Exchange Rateson Operating Income
EffectofExchangeRatesonOperatingIncome
3647000 USD
hae Effectof Exchange Rateson Operating Income
EffectofExchangeRatesonOperatingIncome
9746000 USD
hae Effectof Exchange Rateson Operating Income
EffectofExchangeRatesonOperatingIncome
4358000 USD
CY2021Q4 hae Operating Expenses Transaction Costs
OperatingExpensesTransactionCosts
625000 USD
CY2020Q3 hae Operating Expenses Transaction Costs
OperatingExpensesTransactionCosts
1773000 USD
hae Operating Expenses Transaction Costs
OperatingExpensesTransactionCosts
17358000 USD
hae Operating Expenses Transaction Costs
OperatingExpensesTransactionCosts
3063000 USD
CY2021Q4 us-gaap Adjustment For Amortization
AdjustmentForAmortization
11400000 USD
CY2020Q3 us-gaap Adjustment For Amortization
AdjustmentForAmortization
8136000 USD
us-gaap Adjustment For Amortization
AdjustmentForAmortization
23779000 USD
us-gaap Adjustment For Amortization
AdjustmentForAmortization
16399000 USD
CY2021Q4 hae Restructuringand Turnaround Costs
RestructuringandTurnaroundCosts
4513000 USD
CY2020Q3 hae Restructuringand Turnaround Costs
RestructuringandTurnaroundCosts
4440000 USD
hae Restructuringand Turnaround Costs
RestructuringandTurnaroundCosts
14568000 USD
hae Restructuringand Turnaround Costs
RestructuringandTurnaroundCosts
8440000 USD
CY2021Q4 us-gaap Restructuring Reserve Accelerated Depreciation
RestructuringReserveAcceleratedDepreciation
250000 USD
CY2020Q3 us-gaap Restructuring Reserve Accelerated Depreciation
RestructuringReserveAcceleratedDepreciation
576000 USD
us-gaap Restructuring Reserve Accelerated Depreciation
RestructuringReserveAcceleratedDepreciation
3893000 USD
us-gaap Restructuring Reserve Accelerated Depreciation
RestructuringReserveAcceleratedDepreciation
3082000 USD
CY2021Q4 hae European Medical Device Regulation Costs
EuropeanMedicalDeviceRegulationCosts
2347000 USD
CY2020Q3 hae European Medical Device Regulation Costs
EuropeanMedicalDeviceRegulationCosts
736000 USD
hae European Medical Device Regulation Costs
EuropeanMedicalDeviceRegulationCosts
4718000 USD
hae European Medical Device Regulation Costs
EuropeanMedicalDeviceRegulationCosts
1489000 USD
CY2021Q4 us-gaap Litigation Settlement Expense
LitigationSettlementExpense
145000 USD
CY2020Q3 us-gaap Litigation Settlement Expense
LitigationSettlementExpense
0 USD
us-gaap Litigation Settlement Expense
LitigationSettlementExpense
1083000 USD
us-gaap Litigation Settlement Expense
LitigationSettlementExpense
0 USD
CY2021Q4 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
0 USD
CY2020Q3 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
31498000 USD
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
9603000 USD
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
31498000 USD
CY2021Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
24510000 USD
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
58782000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
25900000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
70497000 USD
CY2021Q4 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
239897000 USD
CY2020Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
209486000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
468425000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
405063000 USD
CY2021Q4 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
239897000 USD
CY2020Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
209486000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
468425000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
405063000 USD
us-gaap Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax
ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
-1472000 USD
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
11000 USD
CY2021Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-29547000 USD
us-gaap Other Comprehensive Income Loss Before Reclassifications Net Of Tax
OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
-1461000 USD
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-29536000 USD

Files In Submission

Name View Source Status
0000313143-21-000052-index-headers.html Edgar Link pending
0000313143-21-000052-index.html Edgar Link pending
0000313143-21-000052.txt Edgar Link pending
0000313143-21-000052-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
hae-20211002.htm Edgar Link pending
hae-20211002.xsd Edgar Link pending
hae-20211002_cal.xml Edgar Link unprocessable
hae-20211002_def.xml Edgar Link unprocessable
hae-20211002_htm.xml Edgar Link completed
hae-20211002_lab.xml Edgar Link unprocessable
hae-20211002_pre.xml Edgar Link unprocessable
haeq2sep2022ex311.htm Edgar Link pending
haeq2sep2022ex312.htm Edgar Link pending
haeq2sep2022ex321.htm Edgar Link pending
haeq2sep2022ex322.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending